HomeCompareCUGCY vs PFE

CUGCY vs PFE: Dividend Comparison 2026

CUGCY yields 0.71% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $29.8K in total portfolio value· pulled ahead in Year 8
10 years
CUGCY
CUGCY
● Live price
0.71%
Share price
$4.20
Annual div
$0.03
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19.8K
Annual income
$0.07
Full CUGCY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — CUGCY vs PFE

📍 PFE pulled ahead of the other in Year 8

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCUGCYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CUGCY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CUGCY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CUGCY
Annual income on $10K today (after 15% tax)
$60.71/yr
After 10yr DRIP, annual income (after tax)
$0.06/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $22,319.84/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CUGCY + PFE for your $10,000?

CUGCY: 50%PFE: 50%
100% PFE50/50100% CUGCY
Portfolio after 10yr
$34.7K
Annual income
$13,129.40/yr
Blended yield
37.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

CUGCY
No analyst data
Altman Z
2.6
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CUGCY buys
0
PFE buys
0
No recent congressional trades found for CUGCY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCUGCYPFE
Forward yield0.71%6.13%
Annual dividend / share$0.03$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%13.2%
Portfolio after 10y$19.8K$49.6K
Annual income after 10y$0.07$26,258.71
Total dividends collected$72.00$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CUGCY vs PFE ($10,000, DRIP)

YearCUGCY PortfolioCUGCY Income/yrPFE PortfolioPFE Income/yrGap
1$10,736$35.71$9,153$693.39+$1.6KCUGCY
2$11,505$17.92$8,593$849.25+$2.9KCUGCY
3$12,319$8.97$8,336$1,066.78+$4.0KCUGCY
4$13,186$4.49$8,437$1,384.80+$4.7KCUGCY
5$14,112$2.25$9,013$1,875.40+$5.1KCUGCY
6$15,101$1.12$10,306$2,680.72+$4.8KCUGCY
7$16,158$0.56$12,820$4,101.38+$3.3KCUGCY
8← crossover$17,289$0.28$17,673$6,826.70$384.00PFE
9$18,500$0.14$27,543$12,591.86$9.0KPFE
10$19,795$0.07$49,560$26,258.71$29.8KPFE

CUGCY vs PFE: Complete Analysis 2026

CUGCYStock

China Oriental Group Company Limited manufactures and sells iron and steel products for downstream steel manufacturers in the People's Republic of China. It operates through Iron and Steel, and Real Estate segments. The company offers H-section steel products for use in non-residential construction and infrastructure projects; strips and strip products; cold rolled sheets for use in manufacturing home electric appliances, hardware, pipes, etc.; galvanized sheets for production of civil-purpose sheets; billets for use as substrate in downstream steel products; and rebars for use in residential and non-residential projects. It also engages in the trade of steel, and iron ore and related products; leasing and financial leasing business; import and export of goods and technology; purchase and sale of ferrous metal and coke; development and sale of real estate properties; environmental protection engineering activities; non-metallic ore mining and trading; recycling of steel and waste materials; manufacture and sale of power transmission facilities; manufacturing of casting products; and research and development of recycling and energy-saving technology, as well as other recycling and construction engineering business. In addition, the company provides equipment maintenance, publication, construction project management, wholesale trade, asset management, logistics, commercial management, hotel and catering, cargo transit agency, and investment and management services; and architectural design, sale, and installation services, commercial consulting, technical advisory and software development, technology promotion, and new material technology and building engineering design services. Further, it offers factoring, capital market, and calligraphy and art training services; waste resources utilization services; produces and sells electricity; and sells metal materials and renewable resources. The company was incorporated in 2003 and is based in Wan Chai, Hong Kong.

Full CUGCY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this CUGCY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CUGCY vs SCHDCUGCY vs JEPICUGCY vs OCUGCY vs KOCUGCY vs MAINCUGCY vs JNJCUGCY vs MRKCUGCY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.